Mantas Jesus B 4

What Happened

• Mantas Jesus B, a director of Biogen (BIIB), received a grant of 1,505 restricted stock units (transaction code A) on June 9, 2026. The filing reports the acquisition price as $0.00 (total reported value $0) because these are restricted stock unit awards, not an open-market purchase.

Key Details

• Transaction date: June 9, 2026; Form 4 filed: June 11, 2026 (appears timely under the standard 2-business-day Form 4 filing window).
• Shares/units granted: 1,505 RSUs; acquisition price reported: $0.00.
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Footnote: RSUs vest on the earlier of (i) the next annual meeting or (ii) the one-year anniversary of the grant date (June 9, 2026).
• Transaction type: Award/Grant (code A). No 10b5-1 plan, tax withholding or sale information reported in this summary.

Context

• RSUs are awards that convert into common shares upon vesting and may be forfeited if vesting conditions aren’t met; the immediate grant itself is not an open-market purchase or sale and does not by itself signal a buy/sell decision by the insider.